Evotec (NASDAQ:EVO) Shares Down 6.7% – Time to Sell?

Evotec AG (NASDAQ:EVO – Get Free Report) shares were down 6.7% during trading on Tuesday. The company traded as low as $1.49 and last traded at $1.4550. 44,695 shares were traded during mid-day trading, a decline of 55% from the average daily volume of 100,069 shares. The stock had previously closed at $1.56.

Analyst Ratings Changes

Several research analysts have recently commented on the company. HC Wainwright raised their price objective on Evotec from $4.00 to $5.00 and gave the stock a “buy” rating in a research note on Friday, November 6th. Weiss Ratings downgraded Evotec from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, August 25th. One research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $3.50.

Get Our Latest Analysis on EVO

Evotec Stock Performance

The company has a debt-to-equity ratio of 0.65, a quick ratio of 2.19 and a current ratio of 2.32. The business’s 50 day moving average is $1.59 and its two-hundred day moving average is $2.42.

Institutional Trading of Evotec

A hedge fund recently raised its position in Evotec stock. Optiver Holding B.V. boosted its holdings in Evotec AG (NASDAQ:EVO – Free Report) by 598.4% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 283,576 shares of the company’s stock after purchasing an additional 242,973 shares during the quarter. Optiver Holding B.V. owned approximately 0.08% of Evotec worth $709,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 5.81% of the company’s stock.

Evotec Company Profile

(Get Free Report)

Evotec SE is a life sciences company headquartered in Hamburg, Germany, that provides drug discovery and development services to pharmaceutical, biotechnology and academic partners. Its work spans early-stage research through preclinical and clinical development, using expertise in areas such as biology, chemistry and data-driven drug discovery. The company supports programs across multiple therapeutic areas and develops both small-molecule and biologic medicines. Its Just-Evotec Biologics business focuses on the development and production of biologics, including services intended to help partners advance treatments from research toward clinical and commercial use.

Further Reading

Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.